Coagulopathy

National Hemophilia Foundation and Takeda Partner with Alex Borstein to Raise Awareness of von Willebrand Disease

Monday, August 10, 2020 - 3:00pm

Her brother and uncle live with hemophilia A, her daughter has mild hemophilia, and Alex herself is a carrier of the disease.

Key Points: 
  • Her brother and uncle live with hemophilia A, her daughter has mild hemophilia, and Alex herself is a carrier of the disease.
  • "Taking an active role in the bleeding disorder community isn't a choice for me; it's a responsibility," said Borstein.
  • "Von Willebrand disease affects millions of Americans but is often overlooked, even by some healthcare professionals.
  • Takeda is proud to partner with NHF to help raise awareness around VWD.

Takeda to Present Rare Bleeding Disorders Research Highlighting Need for Real-World Evidence at NHF Bleeding Disorders Conference 2020

Saturday, August 1, 2020 - 4:00pm

Takeda Pharmaceutical Company Limited ( TSE: 4502/NYSE:TAK ) (Takeda), today presented three abstracts at the 72nd National Hemophilia Foundations Bleeding Disorders Conference, underscoring the need for real-world evidence (RWE) to advance patient-centric treatment in bleeding disorders.

Key Points: 
  • Takeda Pharmaceutical Company Limited ( TSE: 4502/NYSE:TAK ) (Takeda), today presented three abstracts at the 72nd National Hemophilia Foundations Bleeding Disorders Conference, underscoring the need for real-world evidence (RWE) to advance patient-centric treatment in bleeding disorders.
  • These data highlight the gaps in diagnosis and treatment still prevalent in the bleeding disorders community today, and spotlight opportunities for Takeda to better support these patients.
  • We have 70+ years of experience driving innovation for patients and a broad portfolio of 11 products across multiple bleeding disorders.
  • Our experience as leaders in hematology means we are well prepared to meet todays needs as we pursue future developments in the treatment of bleeding disorders.

Novalis Invests in Enzyre to Support Development of Enzypad, a Breakthrough Hand-Held Diagnostic and Monitoring Device

Monday, July 27, 2020 - 7:00am

The first application of Enzypad will revolutionize monitoring of hemophilia by providing a real-time picture of a patients blood coagulation status.

Key Points: 
  • The first application of Enzypad will revolutionize monitoring of hemophilia by providing a real-time picture of a patients blood coagulation status.
  • In December 2019, Enzyre signed a collaboration with Takeda for the development of Enzypad in congenital bleeding disorders, validating this innovative approach.
  • Dirk Pollet, CEO of Enzyre commented: We are pleased to welcome Novalis Biotechnology Incubation to our investor base.
  • Enzyre, based in Nijmegen, The Netherlands, is a spin-out from Radboud University Medical Center, developing Enzypad, a near patient diagnostic and monitoring device initially focused on blood coagulation.

Takeda Provides Updates on Its Pharmacokinetic-guided Prophylaxis Studies at ISTH 2020, Reinforcing Its Commitment to Advancing Personalized Care for People with Bleeding Disorders

Sunday, July 12, 2020 - 1:30pm

Takeda presented a total of 13 abstracts at ISTH 2020, available on the ISTH Congress Abstracts Site .

Key Points: 
  • Takeda presented a total of 13 abstracts at ISTH 2020, available on the ISTH Congress Abstracts Site .
  • Among them, Takeda spotlighted four abstracts which support its personalized care approach for patients with bleeding disorders, especially hemophilia and VWD.
  • The data presented at ISTH 2020 demonstrate the value that innovative, personalized approaches provide to the management of hemophilia.
  • Findings presented at ISTH 2020 reaffirm Takedas commitment to support personalized care as the optimal treatment approach for patients with bleeding disorders, added Dr. med.

Majority (55 Percent) of Americans Taking Blood Thinners Indicate They Fear Suffering From Major Bleeding; 73 Percent More Cautious With Routine Activities to Avoid Risk

Tuesday, June 23, 2020 - 1:00pm

Among the 55 percent who said they fear major bleeding, nearly three-quarters (72 percent) say this concern has impacted their quality of life.

Key Points: 
  • Among the 55 percent who said they fear major bleeding, nearly three-quarters (72 percent) say this concern has impacted their quality of life.
  • Blood thinners can save lives, helping to treat and prevent dangerous blood clots, but can also pose a potentially serious side effect: Bleeding.
  • Since blood thinners slow the clotting of blood, unwanted and sometimes dangerous bleeding can occur with the use of these medications2.
  • To learn more about blood clot risks and also the signs and symptoms of blood clots, visit www.stoptheclot.org/guide

Global Bleeding Disorders Therapeutics Market 2020-2024 | Evolving Opportunities with Baxter International Inc. and Bayer AG | Technavio

Wednesday, April 29, 2020 - 1:00am

The global bleeding disorders therapeutics market is expected to grow by USD 4.32 billion as per Technavio.

Key Points: 
  • The global bleeding disorders therapeutics market is expected to grow by USD 4.32 billion as per Technavio.
  • View the full release here: https://www.businesswire.com/news/home/20200428005840/en/
    Technavio has announced its latest market research report titled Global Bleeding Disorders Therapeutics Market 2020-2024 (Graphic: Business Wire)
    Read the 120-page report with TOC on "Bleeding Disorders Therapeutics Market Analysis Report by Type (Hemophilia A, Hemophilia B, Von Willebrand disease, and Other disorders), Geography (Asia, Europe, North America, and ROW), and the Segment Forecasts, 2020-2024".
  • In addition, the R&D of novel therapies is anticipated to boost the growth of the bleeding disorders therapeutics market.
  • Private and government organizations across the world are undertaking various initiatives to create awareness about the availability of medicines for bleeding disorders.

LFB Announces FDA Approval of SEVENFACT®, a New Recombinant Coagulation Factor VIIa, for the Treatment of Adults and Adolescents with Hemophilia A or B with Inhibitors

Monday, April 6, 2020 - 12:00pm

Denis Delval LFBs Chairman and Chief Executive Officer, stated: We are very pleased with the FDA approval of SEVENFACT which provides a new treatment option for hemophilia patients.

Key Points: 
  • Denis Delval LFBs Chairman and Chief Executive Officer, stated: We are very pleased with the FDA approval of SEVENFACT which provides a new treatment option for hemophilia patients.
  • We will now work towards SEVENFACT registration in Europe and other core countries, in order to offer this therapeutic option to patients.
  • Hemophilia A or B is a congenital bleeding disorder caused by a dysfunction or deficiency of Coagulation Factor (F) VIII or IX, respectively.
  • People with Hemophilia may bleed for a longer time than others after injury or surgery.

FDA Approves Additional Treatment for Adults and Adolescents with Hemophilia A or B and Inhibitors

Wednesday, April 1, 2020 - 6:12pm

"Today's approval provides another treatment option for the control of bleeding episodes in adults and adolescents with hemophilia who have developed inhibitors," said Dr. Peter Marks, M.D., Ph.D., director of the FDA's Center for Biologics Evaluation and Research.

Key Points: 
  • "Today's approval provides another treatment option for the control of bleeding episodes in adults and adolescents with hemophilia who have developed inhibitors," said Dr. Peter Marks, M.D., Ph.D., director of the FDA's Center for Biologics Evaluation and Research.
  • Hemophilia A or B is a congenital bleeding disorder caused by a dysfunction or deficiency of Coagulation Factor (F) VIII or IX, respectively.
  • People with hemophilia may bleed for a longer time than others after injury or surgery.
  • Another study evaluated the safety and pharmacokinetics of three escalating doses of Sevenfactin 15 patients with severe hemophilia A or B with or without inhibitors.

Octapharma demonstrates commitment to improving haemophilia A treatment at the 13th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)

Thursday, February 6, 2020 - 9:01am

Octapharma had a prominent role as a Sponsor of the 13th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) Congress this week, which takes place in The Hague, The Netherlands, from February 57, 2020.

Key Points: 
  • Octapharma had a prominent role as a Sponsor of the 13th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) Congress this week, which takes place in The Hague, The Netherlands, from February 57, 2020.
  • Octapharmas activities at the Congress included a scientific symposium that focused on addressing the needs of patients with haemophilia A.
  • The cumulative incidence of inhibitors and of high-titre inhibitors in 105 PUPs receiving Nuwiq was 27.9% and 17.6%, respectively.
  • Olaf Walter, Board Member at Octapharma, added that This symposium truly demonstrates our commitment at Octapharma to improving the lives of people with bleeding disorders.

Takeda and Virgin Pulse Support Patients with Bleeding Disorders to Adopt Healthier Lifestyles

Friday, December 6, 2019 - 2:41pm

PROVIDENCE, R.I., Dec. 06, 2019 (GLOBE NEWSWIRE) -- Virgin Pulse today announced that Takeda, a leading global pharmaceuticals company, has registered approximately 900 patients with bleeding disorders to take part in the Virgin Pulse Global Challenge to help them develop healthy habits that may last a lifetime.

Key Points: 
  • PROVIDENCE, R.I., Dec. 06, 2019 (GLOBE NEWSWIRE) -- Virgin Pulse today announced that Takeda, a leading global pharmaceuticals company, has registered approximately 900 patients with bleeding disorders to take part in the Virgin Pulse Global Challenge to help them develop healthy habits that may last a lifetime.
  • Takeda is committed to supporting people living with hemophilia and von Willebrand disease (VWD) in achieving their health goals.
  • Takeda has been looking at innovative ways to extend care and support for patients living with these conditions.
  • This desire to find new opportunities to help improve the lives of patients with rare bleeding disorders while promoting inclusion for the community sparked Takedas interest in the Virgin Pulse Global Challenge.